Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Martin Augustin.
Drug Discovery Today | 2002
Andreas Russ; Gabriele Stumm; Martin Augustin; Reinhard Sedlmeier; Sigrid Wattler; Michael Nehls
The flood of raw information generated by large-scale data acquisition technologies in genomics, microarrays and proteomics is changing the early stages of the drug discovery process. Although many more potential drug targets are now available compared with the pre-genomics era, knowledge about the physiological context in which these targets act--information crucial to both discovery and development--is scarce. Random mutagenesis strategies in the mouse provide scalable approaches for both the gene-driven validation of candidate targets in vivo and the discovery of new physiological pathways by phenotype-driven screens.
Acta Neuropathologica | 2006
Martina Rudelius; Andreas Osanger; Stephanie Kohlmann; Martin Augustin; Guido Piontek; Ulrich Heinzmann; Gisela Jennen; Andreas Russ; Kaspar Matiasek; Gabriele Stumm; Juergen Schlegel
Disturbance of intracellular trafficking plays a major role in several neurodegenerative disorders including Alzheimer or Parkinson’s disease. The Chediak–Higashi syndrome (CHS), a life-threatening autosomal recessive disease with frequent mutations in the LYST gene, and its animal model, the beige mouse, are both characterized by lysosomal defects with accumulation of giant lysosomes. Clinically they manifest as hypopigmentation, abnormal bleeding and increased susceptibility to infection with various degrees of involvement of the nervous system. In the course of a recessive N-ethyl-N-nitrosurea (ENU) mutagenesis screen, we identified the first murine missense mutation in the lysosomal trafficking regulator gene (LystIng3618) located at a highly conserved position in the WD40 protein domain. Nearly all described human Lyst alleles lead to protein truncation and fatal childhood CHS. Only four different missense mutations have been reported in patients with adolescent or adult forms of CHS involving the nervous system. Interestingly, the LystIng3618 model presents with a predominant neurodegenerative phenotype with progressive degeneration and loss of Purkinje cells and lacks severe impairment of the immune system. Therefore, the LystIng3618 allele could represent a new model for adult CHS with neurological impairment. It could also provide an important tool to elucidate the role of neuronal lysosomal trafficking in the pathophysiology of neurodegeneration.
PLOS ONE | 2011
Kathrin M. Engel; Kristin Schröck; Daniel Teupser; Lesca M. Holdt; Anke Tönjes; Matthias Kern; Kerstin Dietrich; Peter Kovacs; Ute Krügel; Holger A. Scheidt; Jürgen Schiller; Daniel Huster; Gudrun A. Brockmann; Martin Augustin; Joachim Thiery; Matthias Blüher; Michael Stumvoll; Torsten Schöneberg; Angela Schulz
G protein-coupled receptors (GPCR) are involved in the regulation of numerous physiological functions. Therefore, GPCR variants may have conferred important selective advantages during periods of human evolution. Indeed, several genomic loci with signatures of recent selection in humans contain GPCR genes among them the X-chromosomally located gene for GPR82. This gene encodes a so-called orphan GPCR with unknown function. To address the functional relevance of GPR82 gene-deficient mice were characterized. GPR82-deficient mice were viable, reproduced normally, and showed no gross anatomical abnormalities. However, GPR82-deficient mice have a reduced body weight and body fat content associated with a lower food intake. Moreover, GPR82-deficient mice showed decreased serum triacylglyceride levels, increased insulin sensitivity and glucose tolerance, most pronounced under Western diet. Because there were no differences in respiratory and metabolic rates between wild-type and GPR82-deficient mice our data suggest that GPR82 function influences food intake and, therefore, energy and body weight balance. GPR82 may represent a thrifty gene most probably representing an advantage during human expansion into new environments.
Science | 2003
Majid Hafezparast; Rainer Klocke; Christiana Ruhrberg; Andreas Marquardt; Azlina Ahmad-Annuar; Samantha Bowen; Giovanna Lalli; Abi S. Witherden; Holger Hummerich; Sharon E. Nicholson; P. Jeffrey Morgan; Ravi Oozageer; John V. Priestley; Sharon Averill; Von R. King; Simon Ball; Jo Peters; Takashi Toda; Ayumu Yamamoto; Yasushi Hiraoka; Martin Augustin; Dirk Korthaus; Sigrid Wattler; Philipp Wabnitz; Carmen Dickneite; Stefan Lampel; Florian Boehme; Gisela Peraus; Andreas Popp; Martina Rudelius
Genomics | 2004
Fabian Runkel; Andreas Marquardt; Claudia Stoeger; E. Kochmann; D. Simon; B. Kohnke; Dirk Korthaus; F. Wattler; Helmut Fuchs; M. Hrabé de Angelis; Gabriele Stumm; Michael Nehls; Sigrid Wattler; Thomas Franz; Martin Augustin
Journal of Investigative Dermatology | 2005
Declan P. Lunny; Erica Weed; Patrick M. Nolan; Andreas Marquardt; Martin Augustin; Rebecca M. Porter
Journal of Investigative Dermatology | 2003
Thomas Peters; Reinhard Sedlmeier; Heinrich Büssow; Fabian Runkel; G.H. Lüers; Dirk Korthaus; Helmut Fuchs; M. Hrabé de Angelis; Gabriele Stumm; Andreas P. Russ; Rebecca M. Porter; Martin Augustin; Thomas Franz
Archive | 2008
Philipp Wabnitz; Heike Schauerte; Hans Allgeier; Martin Augustin; Lutz Zeitlmann; Michael A. Pleiss; Gabriele Stumm; Anke Mueller; Axel Choidas; Bert Klebl; Gerhard Mueller; Wilfried Schwab; Joelle Le; Jackie Macritchie; Don Simpson
Physiological Genomics | 2006
Johannes Grosse; Patrick Tarnow; Holger Römpler; Boris Schneider; Reinhard Sedlmeier; Ulrike Huffstadt; Dirk Korthaus; Michael Nehls; Sigrid Wattler; Torsten Schöneberg; Heike Biebermann; Martin Augustin
Journal of Comparative Physiology B-biochemical Systemic and Environmental Physiology | 2007
Carola W. Meyer; Juliane Neubronner; Jan Rozman; Gabi Stumm; Andreas Osanger; Claudia Stoeger; Martin Augustin; Johannes Grosse; Martin Klingenspor; Gerhard Heldmaier